サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1541671

高脂血症治療薬の市場レポート：医薬品タイプ、エンドユーザー、地域別、2024～2032年

Hyperlipidemia Drugs Market Report by Drug Type (Statins, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, PCSK9 Inhibitors, and Others), End User (Hospitals, Clinics, and Others), and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 146 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
高脂血症治療薬の市場レポート：医薬品タイプ、エンドユーザー、地域別、2024～2032年
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 146 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の高脂血症治療薬の市場規模は2023年に227億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに268億米ドルに達し、2024～2032年の成長率（CAGR）は1.8％になると予測しています。

高脂血症（高コレステロール血症）は、血流中の脂肪レベルが高いことを特徴とする医療的疾患を指します。高脂血症は、脂質/リポ蛋白レベルの異常な上昇であり、脳卒中、末梢血管疾患、アテローム性動脈硬化症、糖尿病、肥満、高血圧、心血管疾患の原因となります。高脂血症は通常、遺伝的要因、不健康な生活習慣、不適切な食事によって引き起こされます。一般的に使用される高脂血症治療薬には、スタチン系薬剤、PCSK9阻害薬、胆汁酸分泌抑制薬、フィブリン酸誘導体、フィブラート系薬剤などがあります。これらの薬剤は、肝臓でのコレステロール産生レベルを低下させると同時に、血流からコレステロールを除去します。

世界中で高脂血症の有病率が増加していることは、市場の成長を促進する重要な要因の一つです。さらに、高コレステロール値や心血管疾患にかかりやすい高齢者人口の増加も、市場の成長を後押ししています。これに伴い、大衆の間で健康意識が高まり、高コレステロール血症の利用可能な治療法に関する認識が高まっていることも、市場の成長を後押ししています。さらに、有効性を高めた新規薬剤クラスの開発など、さまざまな技術の進歩も成長を促す要因となっています。これらの薬剤は、内皮機能と動脈硬化プラークの安定性を改善し、炎症と細胞への損傷を最小限に抑えます。その他の要因としては、バイオメディカル科学セグメントにおける広範な研究開発（R&D）活動や、世界全体の医療インフラの全体的な改善などが挙げられ、市場のさらなる牽引役となることが予想されます。

本レポートで扱う主要質問

  • 2023年の世界の高脂血症治療薬の市場の市場規模は？
  • 2024～2032年にかけての世界の高脂血症治療薬の市場の予想成長率は？
  • 世界の高脂血症治療薬の市場を牽引する主要因は何か？
  • 世界の高脂血症治療薬の市場に対するCOVID-19の影響は？
  • 医薬品タイプ別の高脂血症治療薬の市場の世界の内訳は？
  • 世界の高脂血症治療薬の市場のエンドユーザー別内訳は？
  • 世界の高脂血症治療薬の市場における主要地域は？
  • 世界の高脂血症治療薬の市場における主要参入企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の高脂血症治療薬市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：医薬品タイプ別

  • スタチン
  • 胆汁酸捕捉剤
  • コレステロール吸収阻害剤
  • PCSK9阻害剤
  • その他

第7章 市場内訳：エンドユーザー別

  • 病院
  • クリニック
  • その他

第8章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第9章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第10章 バリューチェーン分析

第11章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第12章 価格分析

第13章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Amgen Inc.
    • AstraZeneca Plc
    • Daiichi Sankyo Company Limited
    • Eli Lilly and Company
    • Esperion Therapeutics Inc.
    • GlaxoSmithKline Pharmaceuticals Limited（GlaxoSmithKline Plc）
    • Immuron Limited
    • Ionis Pharmaceuticals Inc.
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Sanofi S.A.
図表

List of Figures

  • Figure 1: Global: Hyperlipidemia Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Hyperlipidemia Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Hyperlipidemia Drugs Market: Breakup by Drug Type (in %), 2023
  • Figure 4: Global: Hyperlipidemia Drugs Market: Breakup by End User (in %), 2023
  • Figure 5: Global: Hyperlipidemia Drugs Market: Breakup by Region (in %), 2023
  • Figure 6: Global: Hyperlipidemia Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 7: Global: Hyperlipidemia Drugs (Statins) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 8: Global: Hyperlipidemia Drugs (Statins) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 9: Global: Hyperlipidemia Drugs (Bile Acid Sequestrants) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Hyperlipidemia Drugs (Bile Acid Sequestrants) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Hyperlipidemia Drugs (Cholesterol Absorption Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Hyperlipidemia Drugs (Cholesterol Absorption Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Hyperlipidemia Drugs (PCSK9 Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Hyperlipidemia Drugs (PCSK9 Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Hyperlipidemia Drugs (Other Drug Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Hyperlipidemia Drugs (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Hyperlipidemia Drugs (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Hyperlipidemia Drugs (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Hyperlipidemia Drugs (Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Hyperlipidemia Drugs (Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Hyperlipidemia Drugs (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Hyperlipidemia Drugs (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: North America: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: North America: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: United States: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: United States: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Canada: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Canada: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Asia Pacific: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Asia Pacific: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: China: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: China: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Japan: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Japan: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: India: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: India: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: South Korea: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: South Korea: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Australia: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Australia: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Indonesia: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Indonesia: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Others: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Others: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Europe: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Europe: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Germany: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Germany: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: France: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: France: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: United Kingdom: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: United Kingdom: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Italy: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Italy: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Spain: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Spain: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Russia: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Russia: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Others: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Others: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Latin America: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Latin America: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Brazil: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Brazil: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Mexico: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Mexico: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Others: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Others: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Middle East and Africa: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Middle East and Africa: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Global: Hyperlipidemia Drugs Industry: SWOT Analysis
  • Figure 72: Global: Hyperlipidemia Drugs Industry: Value Chain Analysis
  • Figure 73: Global: Hyperlipidemia Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hyperlipidemia Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Hyperlipidemia Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
  • Table 3: Global: Hyperlipidemia Drugs Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 4: Global: Hyperlipidemia Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: Global: Hyperlipidemia Drugs Market Structure
  • Table 6: Global: Hyperlipidemia Drugs Market: Key Players
目次
Product Code: SR112024A2685

The global hyperlipidemia drugs market size reached US$ 22.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 26.8 Billion by 2032, exhibiting a growth rate (CAGR) of 1.8% during 2024-2032.

Hyperlipidemia, or high cholesterol, refers to a medical ailment characterized by high levels of fats in the bloodstream. It is the abnormal elevation of lipids and/or lipoprotein levels that can lead to stroke, peripheral vascular disease, atherosclerosis, diabetes, obesity, hypertension, and cardiovascular diseases. It is usually caused by genetic factors, unhealthy lifestyles and inadequate diet. Some of the commonly used hyperlipidemia drugs include statins, Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors, bile acid sequestrants, fibric acid derivatives or fibrates and combination and miscellaneous antihyperlipidemic agents. These drugs reduce cholesterol production levels in the liver while further removing it from the bloodstream.

The increasing prevalence of hyperlipidemia across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to high levels of cholesterol and cardiovascular diseases, is also driving the market growth. In line with this, rising health consciousness among the masses and growing awareness regarding the available treatment alternatives for hypercholesterolemia is also favoring the market growth. Additionally, various technological advancements, such as the development of novel drug classes with enhanced efficacy, are acting as other growth-inducing factors. These drugs offer improved endothelial function and stability of atherosclerotic plaques and cause minimal inflammation and damage to the cells. Other factors, including the extensive research and development (R&D) activities in the field of biomedical sciences, along with overall improvements in the healthcare infrastructure across the globe, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hyperlipidemia drugs market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on drug type and end user.

Breakup by Drug Type:

Statins

Bile Acid Sequestrants

Cholesterol Absorption Inhibitors

PCSK9 Inhibitors

Others

Breakup by End User:

Hospitals

Clinics

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Amgen Inc., AstraZeneca PLC, Daiichi Sankyo Company Limited, Eli Lilly and Company, Esperion Therapeutics Inc., GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc), Immuron Limited, Ionis Pharmaceuticals Inc., Merck & Co. Inc., Pfizer Inc. and Sanofi S.A.

Key Questions Answered in This Report

  • 1. What was the size of the global hyperlipidemia drugs market in 2023?
  • 2. What is the expected growth rate of the global hyperlipidemia drugs market during 2024-2032?
  • 3. What are the key factors driving the global hyperlipidemia drugs market?
  • 4. What has been the impact of COVID-19 on the global hyperlipidemia drugs market?
  • 5. What is the breakup of the global hyperlipidemia drugs market based on the drug type?
  • 6. What is the breakup of the global hyperlipidemia drugs market based on the end user?
  • 7. What are the key regions in the global hyperlipidemia drugs market?
  • 8. Who are the key players/companies in the global hyperlipidemia drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hyperlipidemia Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Statins
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Bile Acid Sequestrants
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Cholesterol Absorption Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 PCSK9 Inhibitors
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by End User

  • 7.1 Hospitals
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Clinics
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Amgen Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 AstraZeneca Plc
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Daiichi Sankyo Company Limited
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Eli Lilly and Company
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Esperion Therapeutics Inc.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
    • 13.3.6 GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc)
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Immuron Limited
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
    • 13.3.8 Ionis Pharmaceuticals Inc.
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Merck & Co. Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Pfizer Inc.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Sanofi S.A.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
      • 13.3.11.4 SWOT Analysis